EnteroMedics Inc. (ETRM) - NASDAQ
  • Fri, Jun. 10, 7:28 AM
    • Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Neutral by Wedbush. Price target raised to $36 (71% upside) from $14.
    • EnteroMedics (NASDAQ:ETRM) downgraded to Neutral from Buy by Roth Capital Partners. Price target is $0.50 (11% upside).
    • Relypsa (NASDAQ:RLYP) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target maintained at $9 (52% downside risk).
    • Mirati Therapeutics (NASDAQ:MRTX) downgraded to Hold from Buy by Jefferies. Price target lowered to $17 (77% upside) from $27.
    • AbbVie (NYSE:ABBV) downgraded to Market Perform from Outperform by Cowen & Company. Price target lowered to $70 (15% upside) from $77. Downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $65 (7% upside) from $73.
    • WebMD (NASDAQ:WBMD) downgraded to Market Perform from Outperform by William Blair.
    | Fri, Jun. 10, 7:28 AM | 9 Comments
  • Thu, May 5, 5:46 PM
    • EnteroMedics (NASDAQ:ETRM): Q1 EPS of -$0.82 misses by $0.02.
    • Revenue of $0.07M misses by $0.08M.
    • Press Release
    | Thu, May 5, 5:46 PM
  • Wed, Feb. 17, 12:45 PM
    | Wed, Feb. 17, 12:45 PM | 6 Comments
  • Wed, Feb. 17, 7:58 AM
    • EnteroMedics (ETRM) Q4 results: Revenues: $149K; R&D Expense: $1.7M (-43.3%); SG&A: $5.9M (+90.3%); Operating Loss: ($7.6M) (-24.6%); Net Loss: ($6.8M) (-9.7%); Loss Per Share: ($0.95) (+29.1%).
    • FY2015 results: Revenues: $292K; R&D Expense: $8.1M (-26.4%); SG&A: $19.9M (+36.3%); Operating Loss: ($27.9M) (-9.0%); Net Loss: ($25.5M) (+2.3%); Loss Per Share: ($4.27) (+26.1%); Quick Assets: $7.9M (-31.9%).
    • No guidance given.
    | Wed, Feb. 17, 7:58 AM
  • Wed, Feb. 17, 7:04 AM
    • EnteroMedics (NASDAQ:ETRM): Q4 EPS of -$0.95 misses by $0.05.
    • Revenue of $0.15M misses by $0.28M.
    • Press Release
    | Wed, Feb. 17, 7:04 AM
  • Dec. 23, 2015, 8:35 AM
    • EnteroMedics (NASDAQ:ETRM) shareholders approve three proposals, including a 1:15 reverse split of common shares effective January 7.
    • Shareholders also OK an increase in the number of authorized shares issuable after the reverse split and the issuance of common stock underlying convertible notes and warrants issued by the company pursuant to its November 4, 2015 securities purchase agreement with five institutional investors. Under the terms of the deal, EnteroMedics will issue $23.5M in notes and warrants after the reverse split.
    • Net proceeds will fund commercialization activities for the vBloc neurometabolic therapy, clinical and product development, working capital and general corporate purposes.
    | Dec. 23, 2015, 8:35 AM
  • Nov. 9, 2015, 5:28 PM
    • EnteroMedics (NASDAQ:ETRM): Q3 EPS of -$0.04 beats by $0.04.
    • Revenue of $0.07M misses by $0.15M.
    | Nov. 9, 2015, 5:28 PM
  • Aug. 6, 2015, 7:06 AM
    • EnteroMedics (NASDAQ:ETRM): Q2 EPS of -$0.10 in-line.
    | Aug. 6, 2015, 7:06 AM
  • Jul. 7, 2015, 5:18 PM
    • EnteroMedics (NASDAQ:ETRM) prices its downsized public offering of 32M units at $0.50 per unit. Each unit consists of one share of common stock and one Series A warrant to purchase one share of common stock at $0.60 per share.
    • The original offer, announced on June 30, was ~40.2M units at $0.87 per unit.
    • Previously: EnteroMedics prices equity offering; shares off 12% premarket (June 30)
    | Jul. 7, 2015, 5:18 PM
  • Jun. 30, 2015, 9:13 AM
    • Thinly traded nano cap EnteroMedics (NASDAQ:ETRM) eases 12% premarket in response to the company's public offering 40,229,886 units at $0.87 per unit. Each unit consists of one share of common stock, 0.50 of a Series A warrant to purchase one share of common stock at $1.00 and 0.50 of a Series B warrant to purchase one share of common stock at $1.09. Closing date is July 6.
    • Net proceeds will fund commercialization activities, R&D, working capital and general corporate purposes.
    | Jun. 30, 2015, 9:13 AM
  • May 28, 2015, 12:47 PM
    | May 28, 2015, 12:47 PM | 2 Comments
  • May 20, 2015, 9:14 AM
    | May 20, 2015, 9:14 AM | 3 Comments
  • Apr. 30, 2015, 7:49 AM
    • EnteroMedics (NASDAQ:ETRM): Q1 EPS of -$0.10 misses by $0.01.
    | Apr. 30, 2015, 7:49 AM
  • Feb. 18, 2015, 8:36 AM
    • EnteroMedics (ETRM -0.8%) Q4 results: Revenues: $0; R&D Expense: $3M (+3.4%); SG&A: $3.1M (-11.4%); Operating Loss: ($6.1M) (+4.7%); Net Loss: ($6.2M) (+6.1%); Loss Per Share: ($0.09) (+18.2%).
    • FY2014 results: Revenues: $0; R&D Expense: $11M (-0.9%); SG&A: $14.6M (+6.6%); Operating Loss: ($25.6M) (-3.6%); Net Loss: ($26.1M) (-1.2%); Loss Per Share: ($0.39) (+17.0%); Quick Assets: $11.6M (-50.2%).
    • No guidance given.
    | Feb. 18, 2015, 8:36 AM
  • Feb. 18, 2015, 7:06 AM
    • EnteroMedics (NASDAQ:ETRM): Q4 EPS of -$0.09 beats by $0.01.
    | Feb. 18, 2015, 7:06 AM
  • Jan. 15, 2015, 8:13 AM
    • Nano cap EnteroMedics (NASDAQ:ETRM) jumped 19% yesterday on massive turnover of more than 20M shares in response to the FDA clearance of its Maestro obesity device.
    • Reimbursement has yet to be established, however. Rapid adoption of the product by the medical community won't happen until this does, currently 2016 at the earliest for Medicare. Private insurers set their rates based on the Medicare rate so this will seriously constrain market uptake of the device, especially considering the $15K price tag. Until then, patients will have to pay out-of-pocket for the procedure, expected to cost as much as $30K.
    • Roth Capital Partners Chris Lewis says, "There are a lot of patients in this gap between drugs and exercise and changes in diet, and on the other spectrum is the more invasive bariatric surgical options like Lap-Band. This [Maestro] fills that gap. Getting government health agency [Medicare] approval by 2016 is still a "best-case" scenario."
    • Previously: FDA clears new obesity device (Jan. 14)
    | Jan. 15, 2015, 8:13 AM | 3 Comments
Company Description
EnteroMedics, Inc. is a clinical development stage medical device company with approvals to commercially launch its product in Australia and the European Economic Area. It's focused on the designs and development of devices that use neuroblocking technology to treat obesity, metabolic diseases... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States